tradmap

SGMT Earnings Sagimet Biosciences Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$165 -$83 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $1M $2M 2022 2023 2024 2025
Revenue
Net income (annual)
-$51M -$26M $0 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$126 -$63 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $1M $2M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$18M -$9M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–17 of 17
Q2 20262026-06-30-0.572026-08-1110-Q
Q1 20262026-03-31-0.332026-05-1210-Q
FY 20252025-12-31-1.582026-03-1110-K
Q3 20252025-09-30-1.282025-11-1310-Q
Q2 20262025-06-30-0.892026-08-1110-Q
Q1 20262025-03-31-0.562026-05-1210-Q
FY 20252024-12-31-1.452026-03-1110-K
Q3 20252024-09-30-0.952025-11-1310-Q
Q2 20252024-06-30-0.482025-08-1310-Q
Q1 20252024-03-31-0.232025-05-0810-Q
FY 20242023-12-31-2.662025-03-1210-K
Q3 20242023-09-30-3.222024-11-1410-Q
Q2 20242023-06-30-71.392024-08-1410-Q
Q1 20242023-03-31-35.582024-05-1510-Q
FY 20232022-12-31-165.202024-03-2510-K
Q3 20232022-09-30-126.132023-11-1310-Q
Q2 20232022-06-30-85.802023-08-2110-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.